Vortioxetine Hydrobromide Patent Expiration
Vortioxetine Hydrobromide is Used for treating major depressive disorder in adults. It was first introduced by Takeda Pharmaceuticals Usa Inc
Vortioxetine Hydrobromide Patents
Given below is the list of patents protecting Vortioxetine Hydrobromide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Trintellix |
US9278096 (Pediatric) | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity | Sep 21, 2032 | Takeda Pharms Usa |
| Trintellix | US9278096 | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity | Mar 21, 2032 | Takeda Pharms Usa |
| Trintellix |
US8722684 (Pediatric) | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Dec 30, 2031 | Takeda Pharms Usa |
| Trintellix | US8722684 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Jun 30, 2031 | Takeda Pharms Usa |
| Trintellix |
US11458134 (Pediatric) | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Dec 15, 2027 | Takeda Pharms Usa |
| Trintellix |
US8969355 (Pediatric) | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment | Dec 15, 2027 | Takeda Pharms Usa |
| Trintellix |
US9125908 (Pediatric) | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Dec 15, 2027 | Takeda Pharms Usa |
| Trintellix |
US9125909 (Pediatric) | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Dec 15, 2027 | Takeda Pharms Usa |
| Trintellix |
US9125910 (Pediatric) | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Dec 15, 2027 | Takeda Pharms Usa |
| Trintellix |
US9227946 (Pediatric) | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment | Dec 15, 2027 | Takeda Pharms Usa |
| Trintellix |
US9861630 (Pediatric) | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Dec 15, 2027 | Takeda Pharms Usa |
| Trintellix | US11458134 | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Jun 15, 2027 | Takeda Pharms Usa |
| Trintellix | US8969355 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment | Jun 15, 2027 | Takeda Pharms Usa |
| Trintellix | US9125908 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Jun 15, 2027 | Takeda Pharms Usa |
| Trintellix | US9125909 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Jun 15, 2027 | Takeda Pharms Usa |
| Trintellix | US9125910 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Jun 15, 2027 | Takeda Pharms Usa |
| Trintellix | US9227946 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment | Jun 15, 2027 | Takeda Pharms Usa |
| Trintellix | US9861630 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | Jun 15, 2027 | Takeda Pharms Usa |
| Trintellix |
US7144884 (Pediatric) | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | Dec 17, 2026 | Takeda Pharms Usa |
| Trintellix | US7144884 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | Jun 17, 2026 | Takeda Pharms Usa |
| Trintellix | US8476279 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Oct 02, 2022
(Expired) | Takeda Pharms Usa |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vortioxetine Hydrobromide's patents.
Latest Legal Activities on Vortioxetine Hydrobromide's Patents
Given below is the list recent legal activities going on the following patents of Vortioxetine Hydrobromide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Aug, 2023 | US9278096 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Jun, 2023 | US9227946 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Feb, 2023 | US9125908 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Feb, 2023 | US9125910 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Feb, 2023 | US9125909 |
| Post Issue Communication - Certificate of Correction | 10 Nov, 2022 | US11458134 |
| Recordation of Patent Grant Mailed Critical | 04 Oct, 2022 | US11458134 |
| Patent Issue Date Used in PTA Calculation Critical | 04 Oct, 2022 | US11458134 |
| Email Notification Critical | 15 Sep, 2022 | US11458134 |
| Issue Notification Mailed Critical | 14 Sep, 2022 | US11458134 |
Vortioxetine Hydrobromide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vortioxetine Hydrobromide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets | Seasons Biotechnology (Taizhou) Co., Ltd. | COMPLETED (Apr, 2023) | PHASE1 |
Vortioxetine Hydrobromide Generic API Manufacturers
Several generic applications have been filed for Vortioxetine Hydrobromide.
Given below is the list of companies who have filed for Vortioxetine Hydrobromide generic, along with the locations of their manufacturing plants worldwide.
1. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Vortioxetine Hydrobromide. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 5MG BASE | tablet | Discontinued | ORAL | N/A | Sep 17, 2021 |
| EQ 10MG BASE | tablet | Discontinued | ORAL | N/A | Sep 17, 2021 |
| EQ 20MG BASE | tablet | Discontinued | ORAL | N/A | Sep 17, 2021 |